IMMUNOGEN, INC.

Patent Owner

Follow Compare Add to Portfolio 1Status Updates

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
 
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 110151
 
 
 
C07K PEPTIDES 7161
 
 
 
C07D HETEROCYCLIC COMPOUNDS 54101
 
 
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 10188
 
 
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 990
 
 
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 988
 
 
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 8153
 
 
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 349
 
 
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 290
 
 
 
A01K ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS145

Top Patents (by citation)

Upgrade to the Premium Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2017/0157,264 CROSS-LINKERS AND THEIR USESOct 14, 16Jun 08, 17[A61K, C07K]
2017/0137,440 METHODS FOR THE ACYLATION OF MAYTANSINOLSep 19, 16May 18, 17[C07D]
2017/0106,097 METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY MAYTANSINOID CONJUGATESJun 01, 16Apr 20, 17[A01K, A61K, C07K]
2017/0095,571 Therapeutic Combinations Comprising Anti-FOLR1 ImmunoconjugatesSep 16, 16Apr 06, 17[A61K, C07K]
2017/0080,102 METHODS FOR CHARACTERIZING AND TREATING ACUTE MYELOID LEUKEMIAMay 19, 15Mar 23, 17[C12Q, G01N, A61K]
2017/0081,418 IMMUNOCONJUGATES TARGETING CD138 AND USES THEREOFJun 18, 16Mar 23, 17[A61K, C07K]
2017/0050,985 METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVESJul 21, 16Feb 23, 17[C07D]
2017/0050,986 METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVESJul 21, 16Feb 23, 17[C07D]
2017/0051,011 METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVESJul 21, 16Feb 23, 17[C07K]
2017/0044,266 CYTOTOXIC BENZODIAZEPINE DERIVATIVESJul 27, 16Feb 16, 17[C07D, A61K, C07K]

View all Publication..

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9702881 Diagnostic assays and kits for detection of folate receptor 1Oct 23, 15Jul 11, 17[A61K, G01N, C07K]
9669102 Cytotoxic benzodiazepine derivativesSep 02, 15Jun 06, 17[C07D, A61K, C07K]
9670278 Folate receptor 1 antibodies and immunoconjugates and uses thereofNov 19, 15Jun 06, 17[C12N, C07H, A61K, C07K]
9670279 Folate receptor 1 antibodies and immunoconjugates and uses thereofNov 25, 15Jun 06, 17[C12N, C07H, A61K, C07K]
9670280 Folate receptor 1 antibodies and immunoconjugates and uses thereofDec 15, 15Jun 06, 17[C12N, C07H, A61K, C07K]
9663492 Methods for the preparation of charged crosslinkersDec 15, 15May 30, 17[C07D]
9657100 Folate receptor 1 antibodies and immunoconjugates and uses thereofAug 05, 15May 23, 17[C12N, C07H, A61K, C07K]
9637547 Monoclonal antibodies for detection of folate receptor 1Aug 29, 14May 02, 17[G01N, A61K, C07K]
9624240 Maytansinoid derivatives with sulfoxide linkerMay 21, 15Apr 18, 17[C07D, A61K]
9617270 Cytotoxic benzodiazepine derivativesFeb 13, 15Apr 11, 17[C07D, A61K]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2016/0367,698 CYTOTOXIC BENZODIAZEPINE DERIVATIVESABANJun 01, 16Dec 22, 16[C07D, A61K, C07K]
2016/0060,345 Novel EGFR-Binding Molecules and Immunoconjugates ThereofABANAug 07, 15Mar 03, 16[C07K]
2016/0058,882 CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVESABANMay 22, 15Mar 03, 16[C07D, A61K]
2015/0343,077 Anti-CD37 Immunoconjugate Dosing RegimensABANMay 12, 15Dec 03, 15[A61K, C07K]
2015/0306,242 PROCESS FOR PREPARING STABLE ANTIBODY MAYTANSINOID CONJUGATESABANOct 04, 13Oct 29, 15[A61K, C07K]
2015/0297,744 Anti-FOLR1 Immunoconjugate Dosing RegimensABANMar 27, 15Oct 22, 15[A61K, C07K]
2015/0110,816 METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATESABANJun 04, 14Apr 23, 15[A61K, C07K]
2015/0093,397 Methods for Increasing Efficacy of CD37-Based TherapyABANMar 29, 13Apr 02, 15[G01N, C07K]
2014/0363,451 Anti-FOLR1 Immunoconjugate Dosing RegimensABANMay 13, 14Dec 11, 14[A61K, C07K]
2014/0350,228 USE OF N-HYDROXYSUCCINIMIDE TO IMPROVE CONJUGATE STABILITYABANDec 13, 12Nov 27, 14[A61K]
2014/0212,411 METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATESABANSep 19, 13Jul 31, 14[A61K]
2014/0154,804 METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATESABANFeb 04, 14Jun 05, 14[C07K]
2014/0093,523 Anti-Integrin Immunoconjugates, Methods and UsesABANDec 04, 13Apr 03, 14[A61K]
2013/0295,050 ANTI-IGF-I RECEPTOR ANTIBODIES, DNAS, VECTORS, HOST CELLS AND GENETIC CONSTRUCTSABANSep 14, 12Nov 07, 13[A61K]
2013/0108,620 METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATESABANNov 28, 11May 02, 13[A61K]
2012/0282,282 Methods for Decreasing Ocular Toxicity of Antibody Drug ConjugatesABANApr 04, 12Nov 08, 12[A61P, A61K]
2012/0269,827 Compositions and Methods for Treatment of Ovarian, Peritoneal, and Fallopian Tube CancerABANMar 29, 12Oct 25, 12[A61P, A61K]
2012/0259,100 PROCESS FOR MANUFACTURING CONJUGATES OF IMPROVED HOMOGENEITYABANMar 29, 12Oct 11, 12[C07K]
2012/0226,025 METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATESABANMay 11, 12Sep 06, 12[C07K]
2012/0226,026 POTENT CONJUGATES AND HYDROPHILIC LINKERSABANMay 17, 12Sep 06, 12[C07D, C07K]

View all patents..

Top Inventors for This Owner

Upgrade to the Premium Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.